FY2025 EPS Estimates for Amarin Decreased by Zacks Research

Amarin Corporation PLC (NASDAQ:AMRN) – Equities research analysts at Zacks Research cut their FY2025 earnings per share estimates for Amarin in a research note issued on Thursday, January 22nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($2.93) for the year, down from their previous forecast of ($2.03). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.

Several other equities analysts also recently commented on the company. Wall Street Zen downgraded Amarin from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research note on Wednesday. One equities research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amarin presently has a consensus rating of “Sell” and an average price target of $12.00.

Amarin Stock Performance

Shares of AMRN stock opened at $16.26 on Monday. The stock’s 50 day simple moving average is $14.98 and its 200 day simple moving average is $15.83. Amarin has a twelve month low of $7.08 and a twelve month high of $20.90. The company has a market capitalization of $338.05 million, a price-to-earnings ratio of -6.53 and a beta of 0.72.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMRN. Banque Cantonale Vaudoise acquired a new stake in shares of Amarin in the third quarter worth $32,000. GPS Wealth Strategies Group LLC bought a new stake in Amarin in the 2nd quarter valued at $32,000. Headlands Technologies LLC acquired a new stake in Amarin in the 2nd quarter worth $44,000. Northwestern Mutual Wealth Management Co. grew its position in Amarin by 1,816.7% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 5,450 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Amarin by 13.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 2,008 shares during the period. 22.25% of the stock is currently owned by institutional investors and hedge funds.

More Amarin News

Here are the key news stories impacting Amarin this week:

• Negative Sentiment: Zacks sharply cut EPS forecasts across Amarin’s near-term and medium-term outlook — including large downward revisions to FY2026 (to -$17.05 from -$3.86) and FY2027 (to -$15.33 from -$3.41) and multiple quarterly EPS drops (e.g., Q4/2026 to -$7.56 from -$1.69, and deep cuts to Q1–Q4 2026–2027). Zacks kept a “Hold” rating, but the far-worse loss projections increase downside risk and likely drove selling pressure. MarketBeat AMRN

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.